Stanley Laman Group Ltd. boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 34.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 20,087 shares of the company’s stock after buying an additional 5,189 shares during the period. Stanley Laman Group Ltd.’s holdings in AbbVie were worth $2,152,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. CVA Family Office LLC acquired a new stake in AbbVie in the third quarter valued at approximately $26,000. Harding Loevner LP grew its position in AbbVie by 118.4% in the third quarter. Harding Loevner LP now owns 332 shares of the company’s stock valued at $29,000 after acquiring an additional 180 shares in the last quarter. Joseph P. Lucia & Associates LLC acquired a new stake in AbbVie in the fourth quarter valued at approximately $29,000. James Investment Research Inc. acquired a new stake in AbbVie in the third quarter valued at approximately $32,000. Finally, Roble Belko & Company Inc grew its position in AbbVie by 70.8% in the third quarter. Roble Belko & Company Inc now owns 415 shares of the company’s stock valued at $36,000 after acquiring an additional 172 shares in the last quarter. 67.49% of the stock is owned by institutional investors.
In other AbbVie news, EVP Jeffrey Ryan Stewart sold 25,290 shares of the firm’s stock in a transaction on Tuesday, December 29th. The stock was sold at an average price of $105.00, for a total value of $2,655,450.00. Following the sale, the executive vice president now directly owns 76,259 shares in the company, valued at $8,007,195. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy J. Richmond sold 51,990 shares of the firm’s stock in a transaction on Friday, November 27th. The shares were sold at an average price of $105.00, for a total value of $5,458,950.00. Following the completion of the sale, the executive vice president now owns 51,990 shares in the company, valued at $5,458,950. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
AbbVie (NYSE:ABBV) last posted its earnings results on Tuesday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.85 by $0.07. The company had revenue of $13.86 billion for the quarter, compared to analysts’ expectations of $13.70 billion. AbbVie had a return on equity of 439.24% and a net margin of 18.16%. The firm’s quarterly revenue was up 59.2% compared to the same quarter last year. During the same period last year, the business posted $2.21 earnings per share. On average, equities analysts expect that AbbVie Inc. will post 10.48 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, May 14th. Shareholders of record on Thursday, April 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 4.89%. The ex-dividend date is Wednesday, April 14th. AbbVie’s payout ratio is 58.17%.
Several brokerages have issued reports on ABBV. Morgan Stanley lowered their price objective on shares of AbbVie from $120.00 to $116.00 and set an “overweight” rating for the company in a research report on Thursday, January 28th. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $114.00 price target for the company in a research report on Tuesday, February 9th. Sanford C. Bernstein assumed coverage on shares of AbbVie in a research report on Tuesday, November 10th. They set an “outperform” rating and a $120.00 price target for the company. Royal Bank of Canada raised their price target on shares of AbbVie from $129.00 to $135.00 and gave the stock an “outperform” rating in a research report on Thursday, February 4th. They noted that the move was a valuation call. Finally, BMO Capital Markets assumed coverage on shares of AbbVie in a research report on Wednesday, November 18th. They set an “outperform” rating and a $123.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the stock. AbbVie presently has an average rating of “Buy” and a consensus target price of $114.39.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: Why does a company issue an IPO?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.